Elevated Expression of DecR1 Impairs ErbB2/Neu-Induced Mammary Tumor Development

REFERENCES

• Alli, P. M., M. L. Pinn, E. M. Jaffee, J. M. McFadden, and F. P. Kuhajda. 2005. Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice. Oncogene 24:39–46.
   PubMed Web of Science ®Google Scholar
• Alo, P. L., P. Visca, A. Marci, A. Mangoni, C. Botti, and U. Di Tondo. 1996. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 77:474–482.
   PubMed Web of Science ®Google Scholar
• Alphey, M. S., W. Yu, E. Byres, D. Li, and W. N. Hunter. 2005. Structure and reactivity of human mitochondrial 2,4-dienoyl-CoA reductase: enzyme-ligand interactions in a distinctive short-chain reductase active site. J. Biol. Chem. 280:3068–3077.
   PubMed Web of Science ®Google Scholar
• Andrechek, E. R., W. R. Hardy, P. M. Siegel, M. A. Rudnicki, R. D. Cardiff, and W. J. Muller. 2000. Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proc. Natl. Acad. Sci. USA 97:3444–3449.
   PubMed Web of Science ®Google Scholar
• Buzzai, M., D. E. Bauer, R. G. Jones, R. J. Deberardinis, G. Hatzivassiliou, R. L. Elstrom, and C. B. Thompson. 2005. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene 24:4165–4173.
   PubMed Web of Science ®Google Scholar
• Cianflone, K. M., Z. Yasruel, M. A. Rodriguez, D. Vas, and A. D. Sniderman. 1990. Regulation of apoB secretion from HepG2 cells: evidence for a critical role for cholesteryl ester synthesis in the response to a fatty acid challenge. J. Lipid Res. 31:2045–2055.
   PubMed Web of Science ®Google Scholar
• Dabiri, S., D. Huntsman, N. Makretsov, M. Cheang, B. Gilks, C. Bajdik, K. Gelmon, S. Chia, and M. Hayes. 2004. The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. Mod. Pathol. 17:690–695.
   PubMed Web of Science ®Google Scholar
• Dang, C. V., and G. L. Semenza. 1999. Oncogenic alterations of metabolism. Trends Biochem. Sci. 24:68–72.
   PubMed Web of Science ®Google Scholar
• Dankort, D., B. Maslikowski, N. Warner, N. Kanno, H. Kim, Z. Wang, M. F. Moran, R. G. Oshima, R. D. Cardiff, and W. J. Muller. 2001. Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast cancer. Mol. Cell. Biol. 21:1540–1551.
   PubMed Web of Science ®Google Scholar
• Elstrom, R. L., D. E. Bauer, M. Buzzai, R. Karnauskas, M. H. Harris, D. R. Plas, H. Zhuang, R. M. Cinalli, A. Alavi, C. M. Rudin, and C. B. Thompson. 2004. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 64:3892–3899.
   PubMed Web of Science ®Google Scholar
• Fantin, V. R., J. St.-Pierre, and P. Leder. 2006. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9:425–434.
   PubMed Web of Science ®Google Scholar
• Fillgrove, K. L., and V. E. Anderson. 2001. The mechanism of dienoyl-CoA reduction by 2,4-dienoyl-CoA reductase is stepwise: observation of a dienolate intermediate. Biochemistry 40:12412–12421.
   PubMedGoogle Scholar
• Guy, C. T., R. D. Cardiff, and W. J. Muller. 1992. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell. Biol. 12:954–961.
   PubMed Web of Science ®Google Scholar
• Hatzivassiliou, G., F. Zhao, D. E. Bauer, C. Andreadis, A. N. Shaw, D. Dhanak, S. R. Hingorani, D. A. Tuveson, and C. B. Thompson. 2005. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8:311–321.
   PubMed Web of Science ®Google Scholar
• Kim, H., R. Chan, D. L. Dankort, D. Zuo, M. Najoukas, M. Park, and W. J. Muller. 2005. The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation. Oncogene 24:7599–7607.
   PubMedGoogle Scholar
• Kuhajda, F. P. 2000. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16:202–208.
   PubMed Web of Science ®Google Scholar
• Kuhajda, F. P., K. Jenner, F. D. Wood, R. A. Hennigar, L. B. Jacobs, J. D. Dick, and G. R. Pasternack. 1994. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc. Natl. Acad. Sci. USA 91:6379–6383.
   PubMed Web of Science ®Google Scholar
• Kumar-Sinha, C., K. W. Ignatoski, M. E. Lippman, S. P. Ethier, and A. M. Chinnaiyan. 2003. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res. 63:132–139.
   PubMed Web of Science ®Google Scholar
• Landis, M. D., D. D. Seachrist, F. W. Abdul-Karim, and R. A. Keri. 2006. Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors. Oncogene 25:3325–3334.
   PubMedGoogle Scholar
• Landis, M. D., D. D. Seachrist, M. E. Montanez-Wiscovich, D. Danielpour, and R. A. Keri. 2005. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice. Oncogene 24:5173–5190.
   PubMedGoogle Scholar
• Makretsov, N. A., D. G. Huntsman, T. O. Nielsen, E. Yorida, M. Peacock, M. C. Cheang, S. E. Dunn, M. Hayes, M. van de Rijn, C. Bajdik, and C. B. Gilks. 2004. Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin. Cancer Res. 10:6143–6151.
   PubMed Web of Science ®Google Scholar
• Menendez, J. A., L. Vellon, I. Mehmi, B. P. Oza, S. Ropero, R. Colomer, and R. Lupu. 2004. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc. Natl. Acad. Sci. USA 101:10715–10720.
   PubMed Web of Science ®Google Scholar
• Moadel, R. M., R. H. Weldon, E. B. Katz, P. Lu, J. Mani, M. Stahl, M. D. Blaufox, R. G. Pestell, M. J. Charron, and E. Dadachova. 2005. Positherapy: targeted nuclear therapy of breast cancer with 18F-2-deoxy-2-fluoro-D-glucose. Cancer Res. 65:698–702.
   PubMedGoogle Scholar
• Ookhtens, M., R. Kannan, I. Lyon, and N. Baker. 1984. Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor. Am. J. Physiol. 247:R146–R153.
   PubMed Web of Science ®Google Scholar
• Pizer, E. S., F. D. Wood, G. R. Pasternack, and F. P. Kuhajda. 1996. Fatty acid synthase (FAS): a target for cytotoxic antimetabolites in HL60 promyelocytic leukemia cells. Cancer Res. 56:745–751.
   PubMedGoogle Scholar
• Plas, D. R., and C. B. Thompson. 2005. Akt-dependent transformation: there is more to growth than just surviving. Oncogene 24:7435–7442.
   PubMed Web of Science ®Google Scholar
• Roe, C. R., D. S. Millington, D. L. Norwood, N. Kodo, H. Sprecher, B. S. Mohammed, M. Nada, H. Schulz, and R. McVie. 1990. 2,4-Dienoyl-coenzyme A reductase deficiency: a possible new disorder of fatty acid oxidation. J. Clin. Investig. 85:1703–1707.
   PubMedGoogle Scholar
• Sabine, J. R., S. Abraham, and I. L. Chaikoff. 1967. Control of lipid metabolism in hepatomas: insensitivity of rate of fatty acid and cholesterol synthesis by mouse hepatoma BW7756 to fasting and to feedback control. Cancer Res. 27:793–799.
   PubMedGoogle Scholar
• Siegel, P. M., E. D. Ryan, R. D. Cardiff, and W. J. Muller. 1999. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J. 18:2149–2164.
   PubMed Web of Science ®Google Scholar
• Swinnen, J. V., K. Brusselmans, and G. Verhoeven. 2006. Increased lipogenesis in cancer cells: new players, novel targets. Curr. Opin. Clin. Nutr. Metab. Care 9:358–365.
   PubMed Web of Science ®Google Scholar
• Warburg, O. 1956. On the origin of cancer cells. Science 123:309–314.
   PubMed Web of Science ®Google Scholar
• White, D. E., N. A. Kurpios, D. Zuo, J. A. Hassell, S. Blaess, U. Mueller, and W. J. Muller. 2004. Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 6:159–170.
   PubMed Web of Science ®Google Scholar
• Younes, M., R. W. Brown, D. R. Mody, L. Fernandez, and R. Laucirica. 1995. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res. 15:2895–2898.
   PubMed Web of Science ®Google Scholar
• Younes, M., L. V. Lechago, J. R. Somoano, M. Mosharaf, and J. Lechago. 1996. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res. 56:1164–1167.
   PubMed Web of Science ®Google Scholar
• Zhang, D., L. K. Tai, L. L. Wong, L. L. Chiu, S. K. Sethi, and E. S. Koay. 2005. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol. Cell. Proteomics 4:1686–1696.
   PubMed Web of Science ®Google Scholar